GABA Therapeutics receives approval to begin phase I clinical trials

  This week, GABA Therapeutics, a recent addition to the ATAI Life Sciences portfolio, announced that it has received approval to conduct a phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia. The Alfred Ethics Committee approved a phase I, two-stage, double-blind, placebo-controlled single and multiple dose study to evaluate the pharmacokinetics, pharmacodynamics, […]

Reflections on the progress of psychedelic medicine

Since co-founding ATAI Life Sciences, I’ve been a firm believer in the power of psychedelic medicine to transform the way we understand and treat mental health disorders. We’ve had much to be thankful for over the course of the past few years, but lately I’ve become acutely aware that we’ve turned a corner as a […]